Navigation Links
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of two long-term studies evaluating ambrisentan, an investigational endothelin receptor antagonist (ERA) for the treatment of patients with pulmonary arterial hypertension (PAH). These long-term data are from patients who originally participated in the two pivotal Phase III ARIES studies and AMB-222, a Phase II study of patients who had previously discontinued other ERAs because of liver function abnormalities. These studies were selected for oral presentation at ATS 2007, the International Conference of the American Thoracic Society, taking place in San Francisco, California, May 18-23.

"Pulmonary arterial hypertension is a progressive, life-threatening disease for which new therapies are clearly needed," said Ronald J. Oudiz, MD, Associate Professor of Medicine, UCLA School of Medicine and Director, Liu Center for Pulmonary Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. "The long-term clinical profile observed in these ambrisentan studies is very encouraging."

About the Studies

In the first presentation (Abstract #2307), Dr. Oudiz presented results from an integrated analysis of an ongoing, long-term extension study (ARIES-E) involving patients from the two 12-week Phase III placebo-controlled studies (ARIES-1 and ARIES-2). A total of 383 patients with idiopathic PAH or PAH associated with connective tissue disease, HIV infection, or anorexigen use who received at least one dose of ambrisentan (2.5, 5 or 10 mg once-daily) in ARIES-1, ARIES-2 or ARIES-E were included in the integrated analysis, which reflect data available as of February 2006 (mean exposure = 39 weeks; maximum exposure = 109 weeks).

Improvements in the non placebo-corrected 6-minute walk distance observed during the first 12 weeks of ambrisentan treatment (+37.7 meters) were sus
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/1/2015)... FRANCISCO , July 1, 2015 ... market) is expected to reach USD 49,119.2 million by ... Research, Inc. Monitoring services is expected to remain the ... of USD 1,227.5 million in 2012, and an estimated ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse ...
(Date:6/30/2015)... Scotland , July 1, 2015 ... joins Nu C ana team   ... ProTide technology to develop and commercialise a portfolio of ... Chris McGuigan as Chief Scientific Officer. ... ProTide technology. He is currently Professor of Medicinal Chemistry ...
(Date:6/30/2015)... , June 30, 2015 Velos, Inc., the ... continues to grow and add customers who receive Clinical ... the 62 CTSAs awarded by the National Institutes of ... management. This is among the largest such market shares ... in the CTSA community keeps growing as a result ...
Breaking Medicine Technology:mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3Velos continues adding CTSA customers - 40% now use Velos products 2
... 2011 The Mobile Dog Heart Health Tour is heading ... health examinations at Dreher Dog Park. From 1 to 5 ... on-site heart screenings in a soundproof medical unit, as well ... (Photo:   http://photos.prnewswire.com/prnh/20110127/CG37759 ) Since early 2009, veterinarians ...
... Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUSD) ("Lotus" or ... of medicine and drugs in the People,s Republic of ... investor interest, the Company has obtained land price guidance ... wishes to provide additional details regarding its 2008 purchase ...
Cached Medicine Technology:Vets to Provide Free Dog Heart Checks in West Palm Beach 2Vets to Provide Free Dog Heart Checks in West Palm Beach 3Lotus Pharmaceuticals Provides Inner Mongolia Land Price Guidance from Cha You Qian Qi Government 2
(Date:7/1/2015)... ... ... Author Francesca Camp wasn’t always a steadfast supporter of plastic surgery. But just ... of the practice; a terrible car accident years ago left her injured and in need ... It ? (And What if I Do?): Answers to All Your Questions about Plastic Surgery” ...
(Date:7/1/2015)... ... 2015 , ... After conducting a nationwide executive search ... Center in Oceanside, Calif., has hired Cheryle Bernard-Shaw as chief compliance officer. ... efforts and growing a focus on risk management, Bernard-Shaw will assume her new ...
(Date:7/1/2015)... ... July 01, 2015 , ... Incentivizing the use of generic drugs ... discounts as much as 80% or 90% off the prices for the brand-name products. ... act to mitigate the financial impact of these high-cost generic drugs. The July issue ...
(Date:7/1/2015)... Beach, CA (PRWEB) , ... July 01, 2015 ... ... has returned to the Northbound team as Director of Referral Relations. , ... programs, including Northbound’s Collegebound, where she designed and implemented unique academic curriculum for ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Thule Atmos X4 offers ... tested to ensure it lived up to Thule’s rigorous standards. Due to its Bi-ComponentArmor ... quality Thule owners have come to expect. , The Thule Atmos X4 ...
Breaking Medicine News(10 mins):Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2Health News:Tri-City Medical Center Hires New Chief Compliance Officer 2Health News:Tri-City Medical Center Hires New Chief Compliance Officer 3Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2
... A new study presented at the Annual Congress for Dermatological ... supplement marketed by Paris-based IsoCell Nutra, significantly increased the levels ... claim that SOD has a different mode of action to ... first discovered in 1968, it is the first antioxidant mobilized ...
... reduce the bulging girth of the abdomen in middle aged and ... who have conducted a study showed that regular practice of yoga ... years can lead to arrest of weight gain in obese people ... collected from 15,500 men and women in the age group of ...
... Asia. Foreigners often come to this side of the content ... in their own countries. ,More and more Globetrotters are ... during the monsoons. Why you may ask? Well it’s believed ... therapy is in the rainy months of June, July and ...
... in Pakistan has shown that handwashing ,with soap prevents ... lower respiratory infections. ,These two infections have ... under 5 years of age ,every year in the ... socio economic groups. ,In the current study done in ...
... after consumption of abortion pill cause concern to women consuming ... physicians regarding the latest reports of death of 5 women ... also called as Mifeprex or Mifepristone. Mifeprex is an approved ... The drug was introduced in the market five years ago. ...
... patients have died amid a strike by junior doctors at ... third day Saturday crippling medical services. ,Two patients died ... patients, mostly poor people who have come for treatment from ... real victims of the strike because there is no doctor ...
Cached Medicine News:Health News:New Supplement Found To Be Effective Against Sunburn 2Health News:Ayurvedic Therapies Cashing In On Medical Tourism 2Health News:Fresh warnings to doctors regarding abortion pill 2
... Level 1 enables hospitals ... patient monitors to a ... Our temperature monitoring disposale ... are superior in their ...
... The pause of a heartbeat. The bodys ... rhythmic breathing. These vital signs are yours ... DeRoyals line of Temperature Monitoring products helps ... information needed to provide the most comfortable ...
... a heartbeat. The bodys warmth beneath drapes. ... vital signs are yours to guard, measure, ... Temperature Monitoring products helps you do your ... provide the most comfortable and precise management ...
... The bodys warmth beneath drapes. The life-giving ... are yours to guard, measure, stabilize and ... products helps you do your job, giving ... most comfortable and precise management of your ...
Medicine Products: